Product Review

DoNotAge SIRT6Activator® Review

4.7/5 Editorial scoreRECOMMENDED

SIRT6Activator has genuine product-linked preclinical evidence: DoNotAge supplied the Fucus vesiculosus fucoidan used in the Biashad mouse lifespan cohort. The separate Robbins study supports the broader SIRT6/fucoidan mechanism but used...

Fucoidan (sulphated polysaccharide)

Check price at DoNotAge Read our verdict

Save 10% with code

BB10: 10% off eligible standalone products. Routine, Performance and Yearly Supply have separate offers. Check the discount guide for terms. Offer terms and exclusions

Partner link. We may earn a commission at no extra cost to you.

Full affiliate disclosure

Disclosure: Biohack Blueprint may earn a commission from qualifying DoNotAge purchases, at no extra cost to you. If you decide to buy this product, see our current DoNotAge discount code BB10 terms, exclusions and checkout demonstration. BB10 currently gives 10% off eligible standalone DoNotAge products. The commercial relationship does not change our editorial standards, evidence grading or review conclusions.

By Dr. Khaled Mahmoud, MBBCh

Reviewed by Dr. Amr Yasser, PhD, Dr. Abdulla Mostafa, PhD

· 23 min read

How we scored it

Our editorial recommendation uses a 1–5 scale. We consider the formulation, label clarity, manufacturer quality disclosures, practical use and value for the intended reader. The published rating is an overall editorial judgment; these factors are not separately measured or weighted.

5/5 means a top editorial recommendation for the stated use case. It does not establish clinical effectiveness or mean that we performed laboratory testing. Research strength and safety limitations are assessed separately in this review.

4.7/5 reflects unusually strong product-linked preclinical evidence, direct SIRT6 biochemistry, independent ingredient-level corroboration, defined formulation and dosing, and active randomized human translation. It remains below the top tier because the key lifespan result is still a preprint and no completed standalone human aging-efficacy trial has reported.

Read the review summary

A physician-led evaluation of DoNotAge's fucoidan-based SIRT6 activator: direct mechanism, the product-linked 2025 mouse lifespan preprint, independent fucoidan evidence, current dosing, safety and the human trial pipeline.

SIRT6Activator has genuine product-linked preclinical evidence: DoNotAge supplied the Fucus vesiculosus fucoidan used in the Biashad mouse lifespan cohort. The separate Robbins study supports the broader SIRT6/fucoidan mechanism but used Sigma-Aldrich F8190 rather than DoNotAge-supplied material. Human aging trials using 2.4 g/day are underway; no standalone human efficacy result has yet shown slower biological aging or improved healthspan.

Evidence for an ingredient does not establish the effects of this finished product. See the evidence section for study design, dose and limitations.

DoNotAge SIRT6Activator bottle, a Fucus vesiculosus fucoidan supplement developed to activate SIRT6 View image

DoNotAge SIRT6Activator bottle, a Fucus vesiculosus fucoidan supplement developed to activate SIRT6

Read the full editorial assessment

SIRT6Activator has an unusually strong product-to-research link for an emerging longevity supplement. The 2025 Biashad lifespan preprint states that the Fucus vesiculosus fucoidan used in its in-vivo aging cohort was supplied by DoNotAge.org; the study reported a 13% median-lifespan increase in male mice, slower frailty progression in both sexes and SIRT6-dependent mechanistic evidence.

The separate 2025 Robbins preprint strengthens the broader fucoidan-SIRT6 and senotherapeutic case but is not a second exact-product replication: its principal Fucoidan-FV material was Sigma-Aldrich F8190. Both key fucoidan mouse papers remain preprints as of 22 September 2026.

Human translation is now real rather than hypothetical. PROMETHEUS includes SIRT6Activator at 2.4 g/day within a multimodal program, while NCT07500649 is a randomized, quadruple-masked, placebo-controlled six-month fucoidan/SIRT6Activator study in 60 men aged 50–80. No standalone human efficacy result has yet shown slower biological aging or improved healthspan.

Our 4.7/5 rating therefore reflects product execution and evidence quality within an early-stage category—not proof of human anti-aging efficacy. A completed positive randomized human trial or peer-reviewed replication of the product-linked lifespan result would justify moving closer to the top of the scale.

Formulation strengths and limitations

What stands out

  • Uses a defined Fucus vesiculosus fucoidan source with product-linked preclinical research, rather than an unspecified generic seaweed extract
  • One 2025 lifespan preprint used DoNotAge-supplied fucoidan in vivo; a separate preprint using Sigma F8190 independently supports SIRT6-dependent DNA-repair and senescence biology
  • Three dose options (800 mg, 1,600 mg and 2,400 mg/day) provide flexibility; the 2,400 mg/day option matches the dose being tested in the current randomized NUS SIRT6Activator trial, while the lower tiers remain manufacturer dosing options rather than validated dose-response levels.
  • Vegan capsule with a short excipient list, manufactured to GMP and ISO 9001 standards
  • The fucoidan/SIRT6Activator intervention is now being tested prospectively in a randomized, quadruple-masked NUS aging trial, with University of Rochester, L'Oréal and DoNotAge.org listed as collaborators.

Things to know first

  • No completed human efficacy trial has yet shown SIRT6 target engagement, slower biological aging or improved healthspan from SIRT6Activator; the dedicated randomized trial is still recruiting.
  • The mouse lifespan exposure was far higher than consumer dosing on a simple mg/kg basis and cannot be directly converted into a human dose; a human dose-response relationship has not been established.
  • There is no validated subjective effect or response timeline, so users should not expect a felt signal to confirm that SIRT6 is being activated.
  • The 14-day money-back guarantee is shorter than some competitors offer, and is tiered (full refund unopened, 50% if opened)

Key takeaways

  • Selected purified Fucus vesiculosus fucoidan can directly activate SIRT6 in biochemical assays and is one of the strongest natural-product leads. It is not the only SIRT6 activator: synthetic activators and other natural modulators also exist.
  • The 2025 Biashad lifespan preprint used DoNotAge-supplied Fucus vesiculosus fucoidan in its in-vivo aging cohort and reported a 13% median lifespan increase in males plus slower frailty in both sexes; the female lifespan increase was not significant.
  • The mouse lifespan exposure was far higher than current consumer doses on a simple mg/kg basis. Direct mouse-to-human conversion is not valid, and no human dose-response study has established an optimal SIRT6Activator dose.
  • A randomized, placebo-controlled human fucoidan/SIRT6Activator aging trial is recruiting at NUS, but no completed standalone efficacy result has yet shown slower biological aging or improved healthspan.
  • DoNotAge offers three dosing tiers (800 mg, 1,600 mg and 2,400 mg daily) and a shorter, tiered 14-day money-back guarantee than its main named competitor.
  • Vera Gorbunova, a DoNotAge scientific-advisory-board member, co-authored the key 2025 preprints. The Biashad in-vivo fucoidan was DoNotAge-supplied, while Robbins used Sigma-Aldrich F8190 for its main Fucoidan-FV experiments. These disclosed relationships and sources should be kept separate.
Physician-reviewed GMP & ISO 9001 manufactured Vegan capsule Data Center cross-checked

Formulation

Key facts & composition

Active compound Fucoidan (sulphated polysaccharide) Purified extract of Fucus vesiculosus, a brown seaweed
Dose per capsule 400 mg Standard daily serving is 4 capsules (1,600 mg)
Daily dose options 800 mg, 1,600 mg or 2,400 mg Manufacturer options. The 2,400 mg/day tier matches the current randomized NUS trial dose; lower tiers have not been validated by a SIRT6 dose-response trial.
Capsule format Vegetable cellulose (HPMC) Vegan, no gelatin
Source species Fucus vesiculosus The species used directly in the founding SIRT6-activation research
Testing In-house and third-party lab tested Checked for purity and potency before release
Diet suitability Vegan, non-GMO No animal-derived ingredients or declared common allergens

Composition

Ingredient Amount Form Source
Fucoidan (from Fucus vesiculosus) 400 mg per capsule; 1,600 mg at the standard daily serving of 4 capsules Purified sulphated polysaccharide extract Fucus vesiculosus (bladderwrack), a brown seaweed

Not all fucoidan preparations behave the same way. Biashad 2025 compared multiple fucoidan sources in biochemical SIRT6 assays and used DoNotAge-supplied Fucus vesiculosus fucoidan in the in-vivo aging cohort. The separate Robbins 2025 senescence study principally used Sigma-Aldrich F8190 as its Fucoidan-FV preparation.

Species, molecular composition and purification matter, so an unspecified generic fucoidan should not be assumed equivalent to the product-linked Fucus material or to the research-grade preparations used in other experiments.

Who this is for

Good fit if you're...

Longevity stack builders

Adults already taking NAD+ precursors or resveratrol who want to add a DNA-repair-focused compound working through a distinct pathway

Evidence-comfortable early adopters

Readers comfortable acting on strong preclinical and product-linked mouse evidence while randomized human aging-efficacy results are still pending.

DNA-repair and senescence focused

Adults over about 40 specifically interested in the DNA-repair and cellular-senescence angle on ageing, rather than a general multivitamin approach

Vegans and vegetarians

The vegetable-cellulose capsule and plant-derived active ingredient suit a fully plant-based routine

Probably not for you if...

Anyone wanting fast, felt effects

Consider waiting if you want a supplement with an immediate, symptom-level signal. There is no validated subjective marker or timeline that tells a user whether SIRT6 activation is occurring.

Anyone on blood-thinning medication

Consider waiting if you take warfarin, a DOAC, or antiplatelet medication, until you've checked with your doctor

Pregnant, breastfeeding, or under 18

Consider waiting — no safety data exist for these groups

Readers who want human-trial certainty first

Consider waiting if you want completed randomized human aging outcomes before trying the product. The dedicated NUS trial is recruiting, but efficacy results are not yet available.

How it works

SIRT6Activator's case rests on a specific, well-replicated biochemical finding: fucoidan from a particular seaweed species switches on the SIRT6 enzyme. Here's how that plays out, from the test tube to the mouse cage.

1

A seaweed compound with a specific target

SIRT6 is a nuclear enzyme with deacetylase, long-chain deacylase and mono-ADP-ribosyltransferase activities. These functions contribute to chromatin regulation and DNA-repair signaling.

Fucoidan is a family of sulfated polysaccharides from brown seaweed. A 2017 study identified selected brown-algae fucoidans as direct SIRT6 activators in a purified-enzyme system.

The two major 2025 preprints should not be treated as identical product replications. Biashad's lifespan study used DoNotAge-supplied Fucus vesiculosus fucoidan for the in-vivo aging cohort. Robbins' separate senotherapeutic study used Sigma-Aldrich F8190 as its main Fucoidan-FV preparation and independently supported SIRT6-dependent DNA-repair and senomorphic effects.

2

SIRT6 and DNA repair

SIRT6 coordinates several genome-maintenance functions, including DNA-damage sensing, PARP1 signaling, chromatin regulation, base-excision repair and double-strand-break repair.

This is not entirely mouse-only biology. Primary human fibroblast and chondrocyte studies show age-related SIRT6/repair relationships and experimental repair rescue in human cells. What is missing is in-vivo human target engagement: no person taking oral fucoidan has yet been shown to increase tissue SIRT6-dependent DNA repair.

A 2026 SIRT6 Ser10 mouse preprint adds an important caution: a phosphomimetic variant improved DNA repair while impairing LINE1 repression and shortening male lifespan. Better repair is therefore not, by itself, proof of better longevity.

3

Modulating senescence-related signaling

Senescent cells can accumulate with age and release inflammatory signals. Fucoidan has been investigated for effects on this senescence-associated secretory phenotype and related stress pathways.

The strongest 2025 senescence-focused SIRT6/fucoidan preprint used research-grade Fucus vesiculosus fucoidan, principally Sigma-Aldrich F8190—not DoNotAge product material. It reported reduced senescence/inflammatory readouts in preclinical models.

The effect was only partly SIRT6-dependent in follow-up experiments. This is better described as early senomorphic/anti-senescence signaling evidence than as proof that the supplement clears senescent cells.

4

What SIRT6 modulation does downstream

Genetic SIRT6 overexpression has improved metabolic and lifespan outcomes in several mouse models, and late-life liver gene delivery can shift selected chromatin-aging features toward younger patterns.

The newer literature also shows why that cannot be simplified to “more SIRT6 is broadly better.” SIRT6 effects vary by sex, tissue, substrate and disease; a 2026 Ser10 mouse study even improved DNA repair while worsening LINE1 repression and male lifespan.

This downstream biology supports SIRT6 as a serious therapeutic target. It does not prove that oral fucoidan reproduces the full phenotype of genetic overexpression or that every SIRT6 activity should be maximized.

Research & evidence

24 cited sources · SIRT6 Activator Data Center

The evidence

Sources include research papers and other cited records, such as registered trials. A trial registration is not a published result.

Each claim below is graded A to F: A means consistent, replicated evidence; D means the mechanism is plausible but direct proof is thin or missing. Grades stay honest even where DoNotAge's own marketing goes further.

A Activates SIRT6 directly and selectively Tier 3

Independent biochemical and preclinical studies support direct SIRT6 activation by selected fucoidan preparations. The 2017 primary study established the enzyme-level mechanism; Biashad 2025 extended the case into lifespan and healthspan experiments using DoNotAge-supplied Fucus vesiculosus fucoidan in vivo.

Robbins 2025 provides useful independent mechanistic support for Fucoidan-FV, senescence and SIRT6-dependent DNA repair, but its principal Fucoidan-FV material was Sigma-Aldrich F8190. It should strengthen the ingredient/mechanism case rather than be counted as a second exact-product replication.

Human translation is now prospective: PROMETHEUS includes branded SIRT6Activator at 2.4 g/day, and a separate randomized placebo-controlled aging study is testing 2.4 g/day. Standalone human efficacy results have not yet been published.

Rahnasto-Rilla MK et al. 2017 , Biashad SA et al. 2025 , Robbins PD et al. 2025

B Extends lifespan and reduces frailty in aged mice Tier 3

In the 2025 Biashad preprint, aged mice given DoNotAge-supplied Fucus vesiculosus fucoidan from 15 months of age had a 13% higher median lifespan in males and slower frailty progression in both sexes. Female median lifespan increased 3%, but the difference was not statistically significant.

Fucoidan did not extend lifespan in SIRT6-knockout mice, strongly supporting SIRT6 dependence in that genetic context. This does not exclude other fucoidan targets contributing to the wild-type phenotype.

The grade is B rather than A because the direct product-linked lifespan evidence is a single preprint with a sex-asymmetric lifespan result. Human SIRT6 pharmacology and fucoidan safety/metabolic studies exist, and a dedicated randomized SIRT6Activator aging trial is recruiting, but no completed human efficacy study has reproduced the lifespan or healthspan outcome.

Biashad SA et al. 2025 , Kanfi Y et al. 2012 , Roichman A et al. 2021

B Supports DNA repair and genomic stability Tier 3

DNA repair is one of the deepest and most replicated parts of SIRT6 biology. Independent studies show SIRT6 participates in damage sensing, PARP1 activation, chromatin remodeling and multiple repair pathways.

The evidence is not mouse-only: primary human fibroblast and chondrocyte experiments show age-related SIRT6/repair relationships and experimental rescue of repair capacity. Comparative mammal work also links stronger SIRT6-supported double-strand-break repair with species longevity.

The grade remains B because no oral fucoidan/SIRT6Activator trial has shown increased DNA-repair capacity in living human tissue or fewer DNA-damage-related clinical events. The 2026 Ser10 mouse study also shows why stronger repair alone cannot be treated as a validated longevity surrogate: repair improved while LINE1 control worsened and male lifespan shortened.

Mostoslavsky R et al. 2006 , Mao Z et al. 2011 , Tian X et al. 2019 , Onn L et al. 2020 , Michael Van Meter et al. 2016 , Zhu Xu et al. 2015 , Copp ME et al. 2023 , Zhihui Zhang et al. 2026

C May reduce senescence-related signaling in preclinical models Tier 3

The 2025 Robbins preprint reported senescence-related and inflammatory improvements with research-grade Fucus vesiculosus fucoidan, including Sigma-Aldrich F8190 as the principal Fucoidan-FV preparation. This is ingredient-level evidence, not an exact-product DoNotAge study.

The effects were not purely SIRT6-dependent in every experiment, which supports a broader fucoidan senomorphic mechanism rather than a clean claim that SIRT6 activation clears senescent cells.

The grade stays C because the study is a preprint, the intervention material was not the final commercial product, and no human trial has shown reduced senescent-cell burden or SASP activity from SIRT6Activator.

Robbins PD et al. 2025

C Supports metabolic efficiency in ageing tissue Tier 3

Mice engineered to carry extra SIRT6 keep making new glucose efficiently in the liver into old age, when normal mice lose that ability, and separately keep youthful levels of a signalling gas called hydrogen sulphide that supports metabolic health.

Both findings are genuinely about SIRT6 activity and ageing metabolism, and both are mechanistically well worked out. Neither, however, was produced using fucoidan — they used genetic overexpression of SIRT6 from birth, a different way of raising SIRT6 activity to the fucoidan supplement being reviewed here.

The grade reflects a real and plausible mechanism with a gap between the intervention studied (genetic) and the intervention sold (a fucoidan supplement) that has not yet been closed by a direct study.

Roichman A et al. 2021 , Touitou N et al. 2025

C Cognitive and brain health support Tier 3

SIRT6 brain evidence now includes both loss-of-function biology and direct pharmacological activation. Brain-specific SIRT6 loss in mice produces DNA-damage, Tau and cognitive abnormalities, and human Alzheimer brain tissue has shown lower SIRT6 expression.

A 2024 Science Signaling study went further: SIRT6 deacetylated APP and promoted its degradation, and systemic pharmacological SIRT6 activation improved amyloid pathology and cognitive deficits in APP/PS1 mice. That is direct preclinical intervention evidence, so a D grade is no longer appropriate.

The grade is C rather than B because the cognitive result is still a mouse Alzheimer-model finding using pharmacological SIRT6 activation, not oral fucoidan or DoNotAge SIRT6Activator, and no human dementia trial has shown cognitive benefit from SIRT6 activation.

Kaluski S et al. 2017 , Smirnov D et al. 2023 , Rong Cheng et al. 2024

Evidence last checked 22 September 2026 against all 95 papers in the Biohack Blueprint SIRT6 Data Center, current trial registries, late-2026 SIRT6 publications and source methods for the key fucoidan studies.

Comparison

How it compares

DoNotAge SIRT6Activator® ReviewProHealth Sirtuin 6 Activator Generic/unbranded fucoidan
Active ingredient Fucus vesiculosus fucoidan, single species, matched to the SIRT6-activation research Fucus vesiculosus + Undaria pinnatifida blend (whole-plant extract and powder) Species and extraction method frequently undisclosed
Daily fucoidan dose 800–2,400 mg/day across three tiers 400 mg/day (1 capsule) Varies widely; often below published research ranges
Product-linked research material Yes. DoNotAge supplied the Fucus vesiculosus fucoidan used in the 2025 Biashad in-vivo lifespan cohort. This is a product-linked ingredient source, not proof that the final commercial capsule formulation itself was the tested intervention. No study of ProHealth's current specific Fucus + Undaria blend was identified in our current evidence review. Usually no product-specific published intervention evidence.
Third-party testing transparency In-house plus third-party lab verification Three rounds of independent third-party testing, with results published for the customer to view Rarely disclosed
Money-back guarantee 14 days (full refund unopened, 50% refund if opened) 100 days, no questions asked Varies, often none
Capsule and excipients Vegetable cellulose capsule only, no additional fillers declared Vegetable cellulose capsule plus microcrystalline cellulose and bamboo silica Varies by manufacturer
Subscription flexibility Three dose tiers, annual shipment, cancel anytime Single dose option, subscribe-and-save available Not applicable

Clinical pharmacology

DoNotAge offers 800, 1,600 and 2,400 mg/day options. The 2,400 mg/day dose is now being tested in a randomized human SIRT6Activator aging trial; the lower tiers remain manufacturer dosing options. None has yet been shown superior in a completed human dose-response study, and the high mouse lifespan exposure cannot be directly converted into a human dose.

Dose tiers

TierDoseFrequencyDurationNotes
Starter — 800 mg/day 2 capsules (800 mg) daily Twice daily per manufacturer guidance Ongoing daily use

Manufacturer lower-dose option: 1 capsule before the midday meal and 1 before the evening meal. No human dose-response or timing study has validated this tier as an optimal SIRT6 dose.
Standard — 1,600 mg/day 4 capsules (1,600 mg) daily Twice daily per manufacturer guidance Ongoing daily use

DoNotAge's current standard daily serving: 2 capsules before the midday meal and 2 before the evening meal. The split schedule is manufacturer guidance rather than a clinically validated pharmacokinetic requirement.
Higher dose — 2,400 mg/day 6 capsules (2,400 mg) daily Twice daily per manufacturer guidance Ongoing daily use

3 capsules before the midday meal and 3 before the evening meal per manufacturer guidance. This 2.4 g/day total matches the dose used in the current randomized NUS SIRT6Activator trial, but it has not yet been proven superior to lower doses.

From bench to bedside

PathwayPreclinical findingHuman translationConfidence
Fucoidan-driven SIRT6 activation and DNA repair Fucoidan increases SIRT6 enzyme activity in purified protein assays, human cell lines, and mouse tissue, and the effect is lost when SIRT6 is genetically removed. The core biochemistry has been shown in human cell lines, but no study has measured SIRT6 activity or DNA repair capacity in a person taking oral fucoidan. Moderate
Fucoidan and mouse lifespan Oral fucoidan extended median lifespan by 13% in male mice and reduced frailty in both sexes, with no benefit in SIRT6-knockout mice. Human fucoidan studies now include absorption, immune, metabolic and safety trials, while SIRT6Activator-specific healthy-aging research is underway at 2.4 g/day. No completed human study has yet shown lifespan extension or established that oral fucoidan reproduces the mouse lifespan effect through confirmed SIRT6 target engagement. Low
SIRT6 and human genetic longevity A rare SIRT6 gene variant is modestly more common in Ashkenazi Jewish centenarians and enhances SIRT6's DNA-repair-relevant enzyme activity in the laboratory. Centenarian genetics provide mechanistic human relevance, but the rare centSIRT6 allele enrichment in the small Ashkenazi Jewish cohort did not reach statistical significance. Laboratory studies of the variant showed enhanced genome-stability functions. This is suggestive human genetics, not evidence that naturally higher SIRT6 activity itself caused exceptional longevity. Low to moderate
Senescence-related signaling Research-grade Fucus vesiculosus fucoidan reduced senescence and inflammatory readouts in preclinical models; the effects were only partly SIRT6-dependent. No completed human SIRT6Activator trial has demonstrated reduced senescent-cell burden or senescence-associated inflammatory signaling through confirmed SIRT6 target engagement. Low

Drug interactions

Caution advised

Anticoagulant and antiplatelet medications

Sulphated polysaccharides like fucoidan have documented anticoagulant and antiplatelet activity in the wider pharmacology literature, separate from the SIRT6-specific evidence reviewed above.

Recommendation:

If you take warfarin, a direct oral anticoagulant, aspirin, or another blood-thinning medication, speak with your doctor before starting SIRT6Activator. This is a precautionary, class-level recommendation rather than a finding from a SIRT6-specific trial — DoNotAge's own guidance is similarly general, advising anyone on prescription medication to check with a healthcare provider first.

Bioavailability tips

DoNotAge currently recommends splitting the daily dose around the midday and evening meals. There is no published product-specific pharmacokinetic or SIRT6 target-engagement study showing that this schedule is superior. The Biashad mouse lifespan experiment used continuing exposure through chow and drinking water, not a human-style twice-daily protocol, so timing should be treated as manufacturer guidance.

Special populations

PopulationRecommendationRationale
Pregnancy and breastfeeding Speak to your doctor before use

No safety data exist for fucoidan supplementation during pregnancy or breastfeeding, in this product's evidence base or the wider literature. DoNotAge's own guidance takes the same precautionary position.
Under 18 Not recommended without paediatric medical advice

There is no relevant pediatric dosing, efficacy or long-term safety evidence for SIRT6Activator. SIRT6 biology is developmentally important, so use in minors should not be extrapolated from adult supplement guidance or preclinical aging studies.
Pre-existing thyroid disease Check with your doctor first

Fucoidan is derived from brown seaweed, but purified extracts are not equivalent to whole seaweed and their residual iodine content can vary. The current product page does not provide a product-specific iodine assay. There is no evidence here of clinically meaningful iodine exposure; people with iodine-sensitive thyroid disease or a prescribed iodine restriction can confirm suitability with their clinician.

Therapeutic positioning

SIRT6Activator sits in a specific corner of the longevity-supplement landscape. Here's how it relates to the other compounds people commonly stack alongside it.

NMN and other NAD+ precursors

Different longevity pathway Potentially complementary, but combination benefit unproven

NMN raises NAD+ availability, which can support SIRT6 as well as other sirtuins and PARPs. A direct SIRT6 activator targets the enzyme more specifically. The pathways therefore overlap biologically at NAD+-dependent signaling even though the interventions act at different levels. No randomized human trial has shown that combining NMN with SIRT6Activator produces additive longevity benefit.

Resveratrol

Different sirtuin target Different primary target; not a direct substitute

Resveratrol is much more strongly associated with SIRT1 pharmacology. It can modulate SIRT6 activity or expression in some laboratory systems, but the SIRT6 evidence is secondary and there is no human SIRT6-mediated efficacy result. Resveratrol should not be treated as a direct substitute for a fucoidan-based SIRT6 strategy.

Senolytics (fisetin, quercetin)

Different mechanism, overlapping goal Different mechanism, earlier evidence stage

Senolytics work by selectively killing senescent cells outright. Fucoidan's senescence-related effect, where it exists, appears to work more by quieting senescent cells' inflammatory output than by killing them, and the evidence for that specific effect is earlier-stage than the fisetin and quercetin senolytic literature.

Small-molecule SIRT6 activators (MDL-800 and similar)

Same target, research-stage only Synthetic pharmacology ranges from preclinical to clinical-stage

MDL-800 and UBCS039 are research-stage synthetic SIRT6 activators with extensive cell and animal pharmacology. Forvisirvat/SP-624 is a separate brain-penetrant direct activator that has progressed into human clinical trials. None of these is an approved consumer longevity medicine.

Exercise has the clearest direct human lifestyle association with higher skeletal-muscle SIRT6 expression. Caloric restriction and fasting intersect with broader nutrient-sensing pathways that include SIRT6 mainly through preclinical and mechanistic evidence. A SIRT6-activating supplement is not a substitute for exercise or an evidence-based diet, and it should not be described as a validated fasting or caloric-restriction mimetic.

SIRT6Activator is a supplement, not a medical treatment. It does not replace a cancer screening programme, a bone-density scan, or medical management of an existing condition. Nothing on this page should be read as a claim to diagnose, treat, cure, or prevent any disease.

Reader-exclusive

DoNotAge SIRT6Activator® Review — via DoNotAge

Use code 10% off
  • 14-day return policy
  • One 366-capsule container covers 61–183 days depending on your chosen dose tier (about 61 days at 2,400 mg/day, up to 183 days at 800 mg/day); subscriptions ship the matching number of containers for a 12-month supply
  • Subscriptions ship as a single annual supply and can be paused or cancelled at any time from your DoNotAge account.
  • Fast shipping from DoNotAge
Get 10% off on DoNotAge with BB10 →

DoNotAge handles pricing, fulfilment, and customer support for this product. Biohack Blueprint may earn a commission from purchases made through links on this page, at no extra cost to you. This does not affect our evidence grading or editorial verdict.

About buying through us

Why does Biohack Blueprint recommend a product it earns commission on?

We're upfront about it: buying through our link earns Biohack Blueprint a commission, and DoNotAge gives readers 10% off with our DoNotAge Discount Code, BB10. That relationship doesn't change what the evidence table above says. The grades are set before commercial considerations, and a D-grade claim stays a D-grade claim whether or not we're an affiliate partner.

Does the affiliate relationship change the evidence grading on this page?

No. Every claim on this page is graded against the same A-to-F framework we use for every product review on this site, based on what the cited papers actually show. Where DoNotAge's own marketing overstates what a study found, that gap is called out directly rather than smoothed over.

Is the DoNotAge-funded research a conflict of interest?

It is a disclosed relationship worth knowing about, not a reason to ignore the data. Vera Gorbunova, a senior author on the 2025 preprints, serves on DoNotAge's scientific advisory board among several longevity-company advisory roles. In the Biashad lifespan preprint, the in-vivo Fucus vesiculosus fucoidan was supplied by DoNotAge.

The separate Robbins senotherapeutic preprint used Sigma-Aldrich F8190 as its main Fucoidan-FV preparation, so it is independent support for the ingredient/mechanism rather than a second exact-product study. Independent peer-reviewed replication of the product-linked lifespan result would materially strengthen the commercial evidence chain.

Why is the money-back guarantee shorter than some competitors offer?

DoNotAge offers a 14-day guarantee (full refund unopened, 50% refund if opened), which is shorter than ProHealth's 100-day guarantee on its own SIRT6 activator. We've said so plainly in the comparison table above rather than leaving it out.

What happens if the evidence changes?

This page carries a last-verified date and a revision history. If the Biashad or Robbins preprints are published in peer-reviewed form with different numbers, or if a human trial reports results, we'll update the evidence table and the verdict to match — that's the point of dating and revising the page rather than publishing it once and leaving it static.

Reader questions

What is SIRT6 and why does activating it matter?

SIRT6 is an NAD+-dependent enzyme that regulates chromatin, DNA repair, metabolism, retrotransposon silencing and stress responses. Some measures of SIRT6 abundance or function change with age in specific tissues and models, but there is no single universal human measure showing that all SIRT6 activity simply declines with age. Mouse genetics strongly support its importance for genome maintenance and longevity biology.

Does fucoidan actually reach and activate SIRT6 in the body?

In a test tube, yes, strongly and specifically. In living mice, dietary fucoidan produced measurable downstream effects — lower DNA damage markers, reduced inflammatory gene activity, extended lifespan in males — that disappeared in mice without SIRT6, which is good evidence the pathway is engaged in a whole animal, not just in a dish. Exactly how a large sugar molecule like fucoidan influences an enzyme sitting inside the cell nucleus is not fully worked out; the study authors themselves flag this as an open question.

How long before I'd notice anything?

There is no validated subjective response or timeline for SIRT6 activation. You should not expect a stimulant-like signal, and current research does not tell us that a person who feels different after weeks or months has achieved greater SIRT6 target engagement. Human trials need objective biomarkers to answer that question.

Can I take SIRT6Activator with NMN or resveratrol?

The combination is biologically plausible but untested. NMN can raise NAD+ availability broadly, resveratrol is associated mainly with SIRT1-related biology, and SIRT6Activator targets SIRT6 through fucoidan pharmacology. These pathways are not fully independent, and no randomized human trial has shown that combining them produces additive longevity benefit or defines a unique interaction profile.

Is SIRT6Activator safe with blood thinners?

Speak to your doctor first. Sulphated polysaccharides like fucoidan have documented anticoagulant and antiplatelet activity in the broader pharmacology literature, separate from the SIRT6 evidence reviewed on this page. This is a precautionary, class-level recommendation rather than a finding specific to this product.

Is it safe during pregnancy?

No safety data exist for fucoidan supplementation during pregnancy or breastfeeding. Speak to your doctor before starting, and DoNotAge's own guidance takes the same precautionary position.

Editorial credibility

Portrait of Dr. Khaled Mahmoud, ICU physician and founder of Biohack Blueprint

Author

Dr. Khaled Mahmoud, MBBCh

MBBCh

Critical Care Medicine, Longevity Science & Editorial Direction

Portrait of Dr. Amr Yasser, cardiometabolic and musculoskeletal reviewer for Biohack Blueprint

Reviewer

Dr. Amr Yasser, PhD

MBBCh, PhD, General Surgery, Cardiometabolic Medicine, Musculoskeletal Research

Cardiometabolic, Musculoskeletal, Gut & Bioavailability

Portrait of Dr. Abdulla Mostafa, neuroscience reviewer for Biohack Blueprint

Reviewer

Dr. Abdulla Mostafa, PhD

MBBCh, PhD, Neuroscience, Neurosurgery

Cellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology

4.7/5 reflects unusually strong product-linked preclinical evidence, direct SIRT6 biochemistry, independent ingredient-level corroboration, defined formulation and dosing, and active randomized human translation. It remains below the top tier because the key lifespan result is still a preprint and no completed standalone human aging-efficacy trial has reported.

Ready to try DoNotAge SIRT6Activator® Review?

Use code BB10 for 10% off on DoNotAge.

Shop DoNotAge SIRT6Activator® Review on DoNotAge →

Partner link. Biohack Blueprint may earn a commission at no extra cost to you.

14-day return policy

Related reading

What Is SIRT6? Function, Aging, DNA Repair & Human Evidence

SIRT6 Longevity: Mouse Lifespan, Human Evidence & What Is Proven

SIRT6 and DNA Repair: DSB Sensing, PARP1, BER & Telomeres

Fucoidan SIRT6 Activator: The Evidence, In Mice and Humans

SIRT6 Mechanism & Structure: Catalytic Activities, Regulation and Activators

SIRT6 Activator: Natural Compounds, Synthetic Drugs & Human Evidence

SIRT6 Activator Benefits: What the Evidence Actually Shows

SIRT6 Clinical Trials: Human Evidence, Forvisirvat & Fucoidan Studies

SIRT6 Activator Dosage: Manufacturer Guidance vs Human Trial Doses

SIRT6 Activator Side Effects: Fucoidan, Forvisirvat & Long-Term Risks

Fucoidan Safety: Human Trials, Bleeding Risk & Drug Interactions

How to Increase SIRT6 Naturally: What Human and Preclinical Evidence Supports

Foods That May Support SIRT6: Cyanidin, Black Rice, Berries & Seaweed

Polyphenol SIRT6 Modulators: Cyanidin, Quercetin, Luteolin & Resveratrol

SIRT6, Metabolism & Diabetes: Glucose, Liver, Kidney and Human Evidence

SIRT6, Muscle & Exercise: AMPK, Oxidative Fibers and Human Evidence

SIRT6 and Cancer: Tumor Suppression, Activation Risks & Conflicting Evidence

SIRT6 and Alzheimer’s: Brain DNA Repair, Tau, Mitochondria & Human Evidence

SIRT6, Inflammation & LINE1: NF-κB, cGAS and Inflammaging

SIRT1 vs SIRT3 vs SIRT6: What Each Sirtuin Does and Why It Matters

SIRT6 vs NMN: Direct Enzyme Activation vs NAD+ Support

SIRT6 Therapeutics: Gene Therapy, Activators, Inhibitors & Peptides
  1. The Identification of a SIRT6 Activator from Brown Algae Fucus distichus Rahnasto-Rilla MK, McLoughlin P, Kulikowicz T, Doyle M, Bohr VA, Lahtela-Kakkonen M, Ferrucci L, Hayes M, Moaddel R (2017) . Marine Drugs Read on our Data CenterView on PubMed View on PMC DOI
  2. SIRT6 activator fucoidan extends healthspan and lifespan in aged wild-type mice Biashad SA, Hillpot E, Morandini F, Rechsteiner C, Paige V, Tombline G, Lee M, Zheng Z, Liang Y, Martinez J, Sieczkiewicz N, Zhang Z, Volobaev V, Firsanov D, Simon M, Zhang LJ, Robbins PD, Seluanov A, Gorbunova V (2025) . bioRxiv (preprint) Read on our Data Center DOI
  3. Fucoidans are senotherapeutics that enhance SIRT6-dependent DNA repair Robbins PD, Zhang L, Elsallabi O, Soto-Palma C, Bartz J, Salekeen R, Nunes A, Xu W, Lee K, Hughes B, Zhang B, Mohamed A, McGowan SJ, Angelini L, O'Kelly R, Biashad SA, Hillpot E, Morandini F, Seluanov A, Gorbunova V, Dong X, Niedernhofer LJ (2025) . Research Square (preprint, not peer-reviewed) Read on our Data CenterView on PubMed View on PMC DOI
  4. The sirtuin SIRT6 regulates lifespan in male mice Kanfi Y, Naiman S, Amir G, Peshti V, Zinman G, Nahum L, Bar-Joseph Z, Cohen HY (2012) . Nature Read on our Data CenterView on PubMed DOI
  5. Restoration of energy homeostasis by SIRT6 extends healthy lifespan Roichman A, Elhanati S, Aon MA, Abramovich I, Di Francesco A, Shahar Y, Avivi MY, Shurgi M, Rubinstein A, Wiesner Y, Shuchami A, Petrover Z, Lebenthal-Loinger I, Yaron O, Lyashkov A, Ubaida-Mohien C, Kanfi Y, Lerrer B, Fernández-Marcos PJ, Serrano M, Gottlieb E, de Cabo R, Cohen HY (2021) . Nature Communications Read on our Data CenterView on PubMed View on PMC DOI
  6. Genomic Instability and Aging-like Phenotype in the Absence of Mammalian SIRT6 Mostoslavsky R, Chua KF, Lombard DB, Pang WW, Fischer MR, Gellon L, Liu P, Mostoslavsky G, Franco S, Murphy MM, Mills KD, Patel P, Hsu JT, Hong AL, Ford E, Cheng HL, Kennedy C, Nunez N, Bronson R, Frendewey D, Auerbach W, Valenzuela D, Karow M, Hottiger MO, Hursting S, Barrett JC, Guarente L, Mulligan R, Demple B, Yancopoulos GD, Alt FW (2006) . Cell Read on our Data CenterView on PubMed DOI
  7. SIRT6 promotes DNA repair under stress by activating PARP1 Mao Z, Hine C, Tian X, Van Meter M, Au M, Vaidya A, Seluanov A, Gorbunova V (2011) . Science Read on our Data CenterView on PubMed View on PMC DOI
  8. SIRT6 is Responsible for More Efficient DNA Double-Strand Break Repair in Long-Lived Species Tian X, Firsanov D, Zhang Z, Cheng Y, Luo L, Tombline G, Tan R, Simon M, Henderson S, Steffan J, Goldfarb A, Tam J, Cornwell A, Johnson A, Yang JN, Mao Z, Manta B, Dang W, Zhang Z, Vijg J, Wolfe A, Moody K, Kennedy BK, Bohmann D, Gladyshev VN, Seluanov A, Gorbunova V (2019) . Cell Read on our Data CenterView on PubMed View on PMC DOI
  9. SIRT6 is a DNA double-strand break sensor Onn L, Portillo M, Ilic S, Cleitman G, Stein D, Kaluski S, Shirat I, Slobodnik Z, Einav M, Erdel F, Akabayov B, Toiber D (2020) . eLife Read on our Data CenterView on PubMed View on PMC DOI
  10. JNK phosphorylates SIRT6 to stimulate DNA double-strand break repair in response to oxidative stress by recruiting PARP1 to DNA breaks Michael Van Meter, Matthew Simon, Gregory Tombline, Alfred May, Timothy D. Morello, Basil P. Hubbard, Katie Bredbenner, Rosa Park, David A. Sinclair, Vilhelm A. Bohr, Vera Gorbunova, Andrei Seluanov (2016) . Cell Reports Read on our Data CenterView on PubMed View on PMC DOI
  11. Sirt6 prevents the age-related decline of H2S through the control of one-carbon metabolism Touitou N, Nahum L, Feldman-Trabelsi S, Avivi MY, Aon MA, Naiman S, Rathaus M, Gertler AA, Roichman A, Berkman Dvir L, Bernier M, Banskota N, Beck L, Nagar R, Schwartz Z, Price NL, Harel M, Lerrer B, Ishii I, Senderowitz H, Moaddel R, Geiger T, de Cabo R, Cohen HY (2025) . Proceedings of the National Academy of Sciences of the United States of America Read on our Data CenterView on PubMed View on PMC DOI
  12. Neuroprotective functions for the histone deacetylase SIRT6 Kaluski S, Portillo M, Besnard A, Stein D, Einav M, Zhong L, Ueberham U, Arendt T, Mostoslavsky R, Sahay A, Toiber D (2017) . Cell Reports Read on our Data CenterView on PubMed View on PMC DOI
  13. SIRT6 is a key regulator of mitochondrial function in the brain Smirnov D, Eremenko E, Stein D, Kaluski S, Jasinska W, Cosentino C, Martinez-Pastor B, Brotman Y, Mostoslavsky R, Khrameeva E, Toiber D (2023) . Cell Death and Disease Read on our Data CenterView on PubMed View on PMC DOI
  14. SIRT6 overexpression counteracts chromatin aging in the male murine liver Ron Nagar, Zacharia Schwartz, Almog Katz, Noga Touitou, Efrat Sharon, Kobi Tzdaka, Odeya Waner, Noam Shalev, Rotem Clo, Leah Weiss, Benjamin Epstein, Michel Bernier, Roni B Shtark, Nirad Banskota, Kwan-Wood G Lam, Supriyo De, Nathan L Price, Batia Lerrer, Daniel Z Bar, Rafael de Cabo, Haim Y Cohen (2026) . Nature Communications Read on our Data CenterView on PubMed View on PMC DOI
  15. A rare human centenarian variant of SIRT6 enhances genome stability and interaction with Lamin A Matthew Simon, Jiping Yang, Jonathan Gigas, Eric J Earley, Eric Hillpot, Lei Zhang, Maria Zagorulya, Greg Tombline, Michael Gilbert, Samantha L Yuen, Alexis Pope, Michael Van Meter, Stephan Emmrich, Denis Firsanov, Advait Athreya, Seyed Ali Biashad, Jeehae Han, Seungjin Ryu, Archana Tare, Yizhou Zhu, Adam Hudgins, Gil Atzmon, Nir Barzilai, Aaron Wolfe, Kelsey Moody, Benjamin A Garcia, David D Thomas, Paul D Robbins, Jan Vijg, Andrei Seluanov, Yousin Suh, Vera Gorbunova (2022) . The EMBO Journal Read on our Data CenterView on PubMed View on PMC DOI
  16. PROMETHEUS clinical trial protocol: tailoring healthy ageing with lifestyle and nutraceuticals Ajla Hodzic Kuerec, Lihuan Guan, Weilan Wang, Duarte Barros, Wejdan M. Alenezi, Jozo Grgic, Vanessa K. Wazny, Jordi Morwani-Mangnani, Mazzarine Dotou, Dingding Zhang, Tong Chen, Jiaqiu Wang, Jane Yu Ying Ong, Jian Hua Tay, Natasha To-Anan, Christian R. Sotelo, Atikah D. Binti Naseer Khan, Wester Bruggink, Sabarinath V. Nair, Saiful A. Bin Mohamed Sukor, Shivaji Rikka, Renee Chng Yee Sin, Hui Min Chong, Faiz Bin Mohamed Hashim, Sharon N. Binte Shahul Hameed, Anees B. Binte Abdul Hamid, Xin Jin, Carmina Fuster, Yong Chen, Anna Milani, Cuilin Zhang, Paul Macary, Timothy R. Singham, Karishma Sachaphibulkij, Michael Dunn, Lin Yi, Andrea B. Maier (2026) . GeroScience Read on our Data CenterView on PubMed DOI Clinical Trial
  17. Effects of fucoidan from Fucus vesiculosus in reducing symptoms of osteoarthritis: a randomized placebo-controlled trial Stephen P Myers, Ann M Mulder, Don G Baker, Shelley R Robinson, Margaret I Rolfe, Lyndon Brooks, J Helen Fitton (2016) . Biologics Read on our Data CenterView on PubMed View on PMC DOI
  18. Absorption Study of Mozuku Fucoidan in Japanese Volunteers Kizuku Kadena, Makoto Tomori, Masahiko Iha, Takeaki Nagamine (2018) . Marine Drugs Read on our Data CenterView on PubMed View on PMC DOI
  19. Effects of Ingesting Fucoidan Derived from Cladosiphon okamuranus Tokida on Human NK Cells: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Pilot Study Makoto Tomori, Takeaki Nagamine, Tomofumi Miyamoto, Masahiko Iha (2021) . Marine Drugs Read on our Data CenterView on PubMed View on PMC DOI
  20. Pilot clinical study to evaluate the anticoagulant activity of fucoidan Mohammad R Irhimeh, J Helen Fitton, Ray M Lowenthal (2009) . Blood Coagulation & Fibrinolysis Read on our Data CenterView on PubMed DOI
  21. Phase 1, Single-Center, Double-Blind, Randomized, Placebo-Controlled Studies of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of the Sirtuin 6 Activator SP-624 in Healthy Adults Greg Rigdon, Yuki Prescott, John Hall, Kelly Abernathy, Joel Raskin, William Wargin (2025) . Clinical Pharmacology in Drug Development Read on our Data CenterView on PubMed View on PMC DOI
  22. A phase 2, multicenter, double-blind, randomized, placebo-controlled study of the safety and efficacy of forvisirvat (SP-624) in the treatment of adults with major depressive disorder Joel Raskin, Anita H Clayton, Susan G Kornstein, George I Papakostas, Yuki Prescott, Kelly Abernathy, John Hall, Michael Ackermann, William Wargin, Greg Rigdon, SP-624-201 study investigators (2025) . Current Medical Research and Opinion Read on our Data CenterView on PubMed DOI Clinical Trial
  23. Sirt6 promotes tumor growth and suppresses immune surveillance Yan Wang, Yu Song, Xianqin Song, Nanyang Zhang, Kehua Fang, Xiaotian Chang (2026) . Cancer Cell International Read on our Data CenterView on PubMed View on PMC DOI
  24. The deacetylase SIRT6 reduces amyloid pathology and supports cognition in mice by reducing the stability of APP in neurons Rong Cheng, Ning Bai, Shuhui Liu, Xiong Zhao, Bo Jiang, Wendong Guo, Sunrun Cao, Jingwei Liu, Na Li, Xiaoman Li, Xuan Wu, Fei Yi, Zhuo Wang, Qiqiang Guo, Jiayi Wei, Ming Bai, Xiaoyou Jiang, Xiaoyu Song, Zhuo Wang, Qi Miao, Difei Wang, Yu Di, Hua Liu, Liu Cao (2024) . Science Signaling Read on our Data CenterView on PubMed DOI
  • 1 Sep 2026 Initial review published with the available SIRT6, fucoidan, product-formulation and safety evidence as of September 1, 2026. Later revisions incorporate additional studies and updated clinical-trial information.
First published 1 Sep 2026 · Last verified 22 Sep 2026